It is an inhibitor of the kinase activity of the BRAF kinase that has the valine to aspartate mutation at position 600 (i.e., the BRAF(V600E) kinase) [69], which is present in at least 60% of all melanomas [70]. The gene discussed is BRAF; the disease is melanoma.